Alisertib (MLN8237), an oral selective inhibitor of aurora kinase A, has clinical activity and restores GATA1 expression in patients with myelofibrosis Meeting Abstract
| Authors: | Gangat, N.; Stein, B. L.; Marinaccio, C.; Swords, R.; Watts, J. M.; Gurbuxani, S.; Frankfurt, O.; Altman, J. K.; Wen, J. Q.; Farnoud, N.; Famulare, C.; Patel, A.; Tapia, R.; Handlogten, A.; Dinh, Y. T.; Englund, K.; Patel, S.; Nobrega, J. C.; Tejera, D.; Thomassen, A.; Stein, H.; Gao, J.; Ji, P.; Rampal, R. K.; Giles, F. J.; Tefferi, A.; Crispino, J. D. |
| Abstract Title: | Alisertib (MLN8237), an oral selective inhibitor of aurora kinase A, has clinical activity and restores GATA1 expression in patients with myelofibrosis |
| Meeting Title: | 60th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 132 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2018 Dec 1-4 |
| Meeting Location: | San Diego, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2018-11-29 |
| Language: | English |
| ACCESSION: | WOS:000454837602066 |
| PROVIDER: | wos |
| DOI: | 10.1182/blood-2018-99-110381 |
| Notes: | Meeting Abstract: 688 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
